European Journal of Cancer
Volume 45, Issue 2 , Pages 261-267, January 2009

Evaluation of lymph nodes with RECIST 1.1

  • L.H. Schwartz

      Affiliations

    • Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue (C-276D), NY, USA
    • Corresponding Author InformationCorresponding author: Tel.: +1 (212) 639 5511; fax: +1 (212) 794 4010.
  • ,
  • J. Bogaerts

      Affiliations

    • European Organization for Research and Treatment of Cancer, Data Centre, Brussels, Belgium
  • ,
  • R. Ford

      Affiliations

    • RadPharm, Princeton, NJ, USA
  • ,
  • L. Shankar

      Affiliations

    • Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
  • ,
  • P. Therasse

      Affiliations

    • GlaxoSmithKline Biologicals, Rixensart, Belgium
  • ,
  • S. Gwyther

      Affiliations

    • East Surrey Hospital, Redhill, Surrey, UK
  • ,
  • E.A. Eisenhauer

      Affiliations

    • National Cancer Institute of Canada – Clinical Trials Group, Kingston, ON, Canada

Received 17 October 2008; accepted 29 October 2008. published online 17 December 2008.

Abstract 

Lymph nodes are common sites of metastatic disease in many solid tumours. Unlike most metastases, lymph nodes are normal anatomic structures and as such, normal lymph nodes will have a measurable size. Additionally, the imaging literature recommends that lymph nodes be measured in the short axis, since the short axis measurement is a more reproducible measurement and predictive of malignancy. Therefore, the RECIST committee recommends that lymph nodes be measured in their short axis and proposes measurement values and rules for categorising lymph nodes as normal or pathologic; either target or non-target lesions. Data for the RECIST warehouse are presented to demonstrate the potential change in response assessment following these rules. These standardised lymph node guidelines are designed to be easy to implement, focus target lesion measurements on lesions that are likely to be metastatic and prevent false progressions due to minimal change in size.

Keywords: Response criteria, Solid tumours, Guidelines, Lymph node

 

PII: S0959-8049(08)00875-7

doi:10.1016/j.ejca.2008.10.028

European Journal of Cancer
Volume 45, Issue 2 , Pages 261-267, January 2009